Will AstraZeneca plc, Burberry Group plc And Taylor Wimpey plc Be This Year’s Big Winners?

Should you pile into these 3 stocks right now? AstraZeneca plc (LON: AZN), Burberry Group plc (LON: BRBY) and Taylor Wimpey plc (LON: TW).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in house builder Taylor Wimpey (LSE: TW) were given a boost today after the company released an upbeat trading update. It states that against the backdrop of a positive UK housing market, Taylor Wimpey has been able to increase home completions by 7% to 13,341, with the average selling price on private completions increasing by 9% to £254,000.

The latter has benefitted from the company’s focus on better quality locations and with Taylor Wimpey having a record year-end order book, it appears to be well-positioned to post further gains in 2016.

Encouragingly, Taylor Wimpey has also delivered a record operating margin with it now standing at 20%. This, plus an improved outlook for the company’s Spanish division, means that Taylor Wimpey’s outlook is very positive.

In fact, its bottom line is forecast to rise by 15% in the current year. This puts the company’s shares on a price-to-earnings growth (PEG) ratio of only 0.8, which indicates that strong gains could lie ahead for the company’s investors, with a dividend yield of 5.7% highlighting Taylor Wimpey’s income appeal too.

High yields

Also offering a top-notch outlook for income-seeking investors is AstraZeneca (LSE: AZN). Despite a challenging period that has seen its bottom line come under considerable pressure as a result of the loss of patent protection on numerous key drugs, AstraZeneca has maintained dividend payouts over the last five years. And with it currently yielding 4.3%, it offers a higher yield than the wider index at the present time.

Looking ahead, AstraZeneca has significant total return potential. As well as a strong yield, it’s expected to return to positive profit growth in the coming years as its vast acquisition strategy begins to bear fruit. On this front, AstraZeneca has more potential in 2016 and beyond since its cash flow and balance sheet appear able to accommodate substantially more debt. That means it can make further purchases in order to enhance the company’s drug pipeline.

This, alongside a price-to-earnings (P/E) ratio of just 16.3, indicates that now could be an opportune moment to buy a slice of AstraZeneca ahead of improved performance in 2016 and beyond.

China syndrome?

Meanwhile, 2016 has got off to a poor start for luxury fashion brand Burberry (LSE: BRBY). Its shares have been affected by fears surrounding China’s long-term growth rate since the world’s second-largest economy remains a key growth region for Burberry. Therefore, further turbulence in the Chinese stock market could cause a further deterioration in Burberry’s share price after its 7% decline since the turn of the year.

But in the longer term, Burberry has huge growth potential. That’s because it continues to enjoy a relatively wide economic moat as a result of a high degree of customer loyalty. And with a diverse geographical spread, its reliance on China for long-term growth may not be as strong as is currently perceived by the market. Therefore, Burberry may be able to command a higher rating than its current P/E ratio of 14.3 – especially since it’s forecast to return to positive profit growth in the next financial year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca, Burberry, and Taylor Wimpey. The Motley Fool UK has recommended AstraZeneca and Burberry. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »